Vimta Labs Limited — Investor Meet, 24-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Vimta Labs reported Q1 FY27 total income of 112.9 Cr (+13.7% YoY) and PAT of 21.0 Cr (+11.4% YoY), with EBITDA margins at 36.4%. Despite mixed demand, performance was resilient. Pharma services showed strong growth, and clinical research is recovering. Food testing faced import/export declines, prompting a focus shift to the domestic market. The new Biologics initiative secured its first domestic order in Q1, with significant contribution expected in 2-3 years. FY27 CapEx is projected at 80 Cr. Management remains optimistic about demand and aims for 20-25% annual growth.